<DOC>
	<DOC>NCT01023230</DOC>
	<brief_summary>The purpose of this study is to determine if DV-601, an investigational, therapeutic vaccine will be well-tolerated and induce hepatitis B virus (HBV)-specific virological and immunological responses in chronic hepatitis B (CHB) patients.</brief_summary>
	<brief_title>A Study to Assess DV-601 in Subjects With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Male and female subjects 18 to 65 years of age. Signed informed consent. Diagnosis of CHB and candidates for therapy Normal renal function Women of childbearing potential must have a serum negative pregnancy test at screening. Women of childbearing potential and males whose sexual partners are of childbearing potential must agree to use dual methods of contraception. Liver disease other than CHB Documented coinfection with hepatitis A virus (HAV), hepatitis C virus (HCV), or HIV Previous therapy with interferon alpha. Any other antiviral therapy for chronic hepatitis B within the previous 3 months prior to Screening Visit. Immunosuppressive treatment (e.g. chemotherapy, highdose of steroids) within 6 months of Screening Visit. Evidence of cirrhosis ChildTurcottePugh (CTP) score â‰¥ 7, either currently or at any occasion in the past Clinically significant acute or chronic illnesses, such as autoimmune diseases, collagen vascular disease, immune deficiencies, active or uncontrolled infections, etc. as determined by the investigator and documented in medical history. Malignancy other than curatively treated, superficial skin cancer or carcinoma in situ of the cervix. Participation in any experimental protocol or therapy within 28 days prior to the Screening Visit. Current substance or alcohol abuse that in the opinion of the investigator would interfere with compliance or with interpretation of study results.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DV-601</keyword>
	<keyword>hepatitis B</keyword>
	<keyword>entecavir</keyword>
	<keyword>therapeutic vaccine</keyword>
</DOC>